biOasis Technologies Ord Shs BIOAF

Primary Symbol: V.BTI.H

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > #RareDiseaseDay

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Feb 28, 2023 4:35pm

128 Views

Post# 35310844

RE:#RareDiseaseDay

Cash until March and we are here...
19 days ago Midatech announced its financing with Ladenberg.
BTI was recognized as far more valuable in the Biodexa transaction.
If all that was next for BTI was a financing it should have been announced some time ago.
Something more complicated?

Are the lights even on? Today BTI Tweets that it is committed to developing treatments for rare brain diseases on #RareDiseaseDay. The lights still appear to be on with a commitment.

What happens next?

prophetoffactz wrote:

@BioasisUS

It's #RareDiseaseDay, a day to raise awareness about the challenges faced by people living with rare diseases. At Bioasis, we're committed to developing treatments for rare brain diseases that affect millions of people worldwide.